Atlas Trials

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Clinical trial NCT00696696 · COMPLETED

Trial details

NCT number
NCT00696696
Sponsor
NYU Langone Health
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2007-09-01
Primary completion
2010-11-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.